Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives.

those in the placebo group, whereas HBV-positive patients showed a trend in favor of sorafenib rather than placebo for TTP (HR: 0.74; 95% CI 0.48–1.14; P = 0.18) and OS (HR: 0.74; 95% CI 0.544–1.03; P = 0.08) [ 21 ].

also in 53,322 other papers

revealed a clear trend in favor of lenvatinib over sorafenib (HR 0.82; 95% CI 0.60–1.15) in terms of OS in HBV-positive patients [ 21 ].

also in 19,460 other papers